Cargando…

A Dynamic Quantitative Systems Pharmacology Model of Inflammatory Bowel Disease: Part 1 – Model Framework

A mechanistic, multistate, mathematical model of inflammatory bowel disease (IBD) was developed by including key biological mechanisms in blood and gut, including cell differentiation, cytokine production, and clinical biomarkers. The model structure is consistent between healthy volunteers and IBD...

Descripción completa

Detalles Bibliográficos
Autores principales: Rogers, Katharine V., Martin, Steven W., Bhattacharya, Indranil, Singh, Ravi Shankar Prasad, Nayak, Satyaprakash
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7877855/
https://www.ncbi.nlm.nih.gov/pubmed/32822108
http://dx.doi.org/10.1111/cts.12849
_version_ 1783650251752603648
author Rogers, Katharine V.
Martin, Steven W.
Bhattacharya, Indranil
Singh, Ravi Shankar Prasad
Nayak, Satyaprakash
author_facet Rogers, Katharine V.
Martin, Steven W.
Bhattacharya, Indranil
Singh, Ravi Shankar Prasad
Nayak, Satyaprakash
author_sort Rogers, Katharine V.
collection PubMed
description A mechanistic, multistate, mathematical model of inflammatory bowel disease (IBD) was developed by including key biological mechanisms in blood and gut, including cell differentiation, cytokine production, and clinical biomarkers. The model structure is consistent between healthy volunteers and IBD disease phenotype, with 24 parameters changed between diseases. Modular nature of the model allows for easy incorporation of new mechanisms or modification of existing interactions. Model simulations for steady‐state levels of proteins and cells in the blood and gut using a population approach are consistent with published data. By simulating the response of two clinical biomarkers, C‐reactive protein and fecal calprotectin, to parameter perturbations, the model explores hypotheses for possible treatment mechanisms. With additional experimental validation and addition of drug treatments, the model provides a platform to test hypothesis on treatment effects in IBD.
format Online
Article
Text
id pubmed-7877855
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-78778552021-02-18 A Dynamic Quantitative Systems Pharmacology Model of Inflammatory Bowel Disease: Part 1 – Model Framework Rogers, Katharine V. Martin, Steven W. Bhattacharya, Indranil Singh, Ravi Shankar Prasad Nayak, Satyaprakash Clin Transl Sci Research A mechanistic, multistate, mathematical model of inflammatory bowel disease (IBD) was developed by including key biological mechanisms in blood and gut, including cell differentiation, cytokine production, and clinical biomarkers. The model structure is consistent between healthy volunteers and IBD disease phenotype, with 24 parameters changed between diseases. Modular nature of the model allows for easy incorporation of new mechanisms or modification of existing interactions. Model simulations for steady‐state levels of proteins and cells in the blood and gut using a population approach are consistent with published data. By simulating the response of two clinical biomarkers, C‐reactive protein and fecal calprotectin, to parameter perturbations, the model explores hypotheses for possible treatment mechanisms. With additional experimental validation and addition of drug treatments, the model provides a platform to test hypothesis on treatment effects in IBD. John Wiley and Sons Inc. 2020-08-21 2021-01 /pmc/articles/PMC7877855/ /pubmed/32822108 http://dx.doi.org/10.1111/cts.12849 Text en © 2020 Pfizer Inc. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of the American Society for Clinical Pharmacology and Therapeutics. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Research
Rogers, Katharine V.
Martin, Steven W.
Bhattacharya, Indranil
Singh, Ravi Shankar Prasad
Nayak, Satyaprakash
A Dynamic Quantitative Systems Pharmacology Model of Inflammatory Bowel Disease: Part 1 – Model Framework
title A Dynamic Quantitative Systems Pharmacology Model of Inflammatory Bowel Disease: Part 1 – Model Framework
title_full A Dynamic Quantitative Systems Pharmacology Model of Inflammatory Bowel Disease: Part 1 – Model Framework
title_fullStr A Dynamic Quantitative Systems Pharmacology Model of Inflammatory Bowel Disease: Part 1 – Model Framework
title_full_unstemmed A Dynamic Quantitative Systems Pharmacology Model of Inflammatory Bowel Disease: Part 1 – Model Framework
title_short A Dynamic Quantitative Systems Pharmacology Model of Inflammatory Bowel Disease: Part 1 – Model Framework
title_sort dynamic quantitative systems pharmacology model of inflammatory bowel disease: part 1 – model framework
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7877855/
https://www.ncbi.nlm.nih.gov/pubmed/32822108
http://dx.doi.org/10.1111/cts.12849
work_keys_str_mv AT rogerskatharinev adynamicquantitativesystemspharmacologymodelofinflammatoryboweldiseasepart1modelframework
AT martinstevenw adynamicquantitativesystemspharmacologymodelofinflammatoryboweldiseasepart1modelframework
AT bhattacharyaindranil adynamicquantitativesystemspharmacologymodelofinflammatoryboweldiseasepart1modelframework
AT singhravishankarprasad adynamicquantitativesystemspharmacologymodelofinflammatoryboweldiseasepart1modelframework
AT nayaksatyaprakash adynamicquantitativesystemspharmacologymodelofinflammatoryboweldiseasepart1modelframework
AT rogerskatharinev dynamicquantitativesystemspharmacologymodelofinflammatoryboweldiseasepart1modelframework
AT martinstevenw dynamicquantitativesystemspharmacologymodelofinflammatoryboweldiseasepart1modelframework
AT bhattacharyaindranil dynamicquantitativesystemspharmacologymodelofinflammatoryboweldiseasepart1modelframework
AT singhravishankarprasad dynamicquantitativesystemspharmacologymodelofinflammatoryboweldiseasepart1modelframework
AT nayaksatyaprakash dynamicquantitativesystemspharmacologymodelofinflammatoryboweldiseasepart1modelframework